#### Accepted Manuscript

Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3-benzothiazin-4-ones (pBTZs) with 2,7-dimethylimidazo [1,2-a]pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins

Mark W. Majewski, Rohit Tiwari, Patricia A. Miller, Sanghyun Cho, Scott G. Franzblau, Marvin J. Miller

PII: DOI: Reference:	S0960-894X(16)30197-4 http://dx.doi.org/10.1016/j.bmc1.2016.02.076 BMCL 23630
To appear in:	Bioorganic & Medicinal Chemistry Letters
Received Date: Revised Date: Accepted Date:	<ul><li>17 December 2015</li><li>23 February 2016</li><li>24 February 2016</li></ul>



Please cite this article as: Majewski, M.W., Tiwari, R., Miller, P.A., Cho, S., Franzblau, S.G., Miller, M.J., Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3-benzothiazin-4-ones (pBTZs) with 2,7-dimethylimidazo [1,2-a]pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins, *Bioorganic & Medicinal Chemistry Letters* (2016), doi: http://dx.doi.org/10.1016/j.bmcl.2016.02.076

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

#### **Graphical Abstract**

To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered.

Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3benzothiazin-4-ones (pBTZs) with 2,7dimethylimidazo [1,2-a]pyridine-3carboxylic acids and 7-phenylacetyl cephalosporins.

Mark W. Majewski,<sup>*4a*</sup> Rohit Tiwari,<sup>*4a,c*</sup> Patricia A. Miller,<sup>*a*</sup> Sanghyun Cho,<sup>*b*</sup> Scott G. Franzblau,<sup>*b*</sup> and Marvin J. Miller<sup>*a*</sup>\*

'no, CO₂t-Bu

MABA MIC (7H12) = 2.10  $\mu\text{M}$  MABA MIC (GAS) = 1.43  $\mu\text{M}$ 

MABA MIC (7H12) = 2.03  $\mu\text{M}$  MABA MIC (GAS) = 1.51  $\mu\text{M}$ 



Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com

# Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3-benzothiazin-4-ones (pBTZs) with 2,7-dimethylimidazo [1,2-a]pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins.

Mark W. Majewski,<sup>‡a</sup> Rohit Tiwari,<sup>‡a,c</sup> Patricia A. Miller,<sup>a</sup> Sanghyun Cho,<sup>b</sup> Scott G. Franzblau,<sup>b</sup> and Marvin J. Miller<sup>a</sup>\*

a-Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA b-Institute for Tuberculosis Research, College of Pharmacy, MIC 964, Rm. 412, University of Illinois at Chicago, IL, 60612, USA c-Current Address: Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food & Drug Administration, 10993 New Hampshire Avenue, Silver Spring, MD 20993.

*≠* Both Authors Contributed Equally

#### ARTICLE INFO

ABSTRACT

Article history: Tuberculosis (TB) remains one of the most threatening diseases in the world and the need for development of new therapies is dire. Herein we describe the rationale for the design and Received subsequent syntheses and studies of conjugates between pBTZ and both the imidazopyridine and Revised cephalosporin scaffolds. Overall some compounds exhibited notable anti-TB activity in the Accepted Available online range of 2 to 0.2 µM in the microplate alamar blue (MABA) assay. 2009 Elsevier Ltd. All rights reserved. Keywords: Tuberculosis Benzothiazinones Imidazopyridine Cephalosporin

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), rivals HIV/AIDS as the most notorious single infectious agent, posing a significant risk to global health. In 2013, it was estimated by the World Health Organization that one-third of the world population was infected with latent TB, approximately 9 million people fell ill with TB, and 1.5 million died of TB.<sup>1</sup> The emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) TB have only put further pressure on the medicinal community, as these new strains pose great challenges to existing treatments.<sup>2</sup> Further, the classic TB drug regimens have many issues associated with them, such as long treatment duration and adverse drug-drug interactions.<sup>3</sup> In an effort to expand structure-activity-relationship studies of potential anti-TB agents, we were interested in designing hybrid scaffolds. Herein, we describe the synthetic coupling of piperazino-1,3-benzothiazin-4-ones  $(pBTZs)^4$  with 2,7-dimethylimidazo [1,2alpyridine-3-carboxylic acids and cephalosporins and anti-TB evaluations of the synthesized conjugates.

The current TB treatment regimen for drug sensitive forms of the disease is long and involves at least 6 months of therapy involving many of the front line orally active anti-TB agents (e.g. rifampin, isoniazid).<sup>5</sup> This approach often suffers from poor patient compliance and can further lead to the progression of drug resistant TB forms. One potential way of slowing resistance has been the use of drug cocktails that keep the mycobacterial population in check by inhibiting not one, but multiple biochemical processes.<sup>6</sup> Fortunately, a number of promising anti-TB agents in development have distinct targets. Nitroimidazoles (PA-824),<sup>7</sup> benzothiazinones (BTZ043),<sup>8</sup> and imidazopyridines carboxamides<sup>9</sup> all have been reported to be potent anti-TB agents (Figure 1) and do not share target similarities.



Figure 1. Promising anti-TB agents currently in development.

Work by Makarov et al. have shown that combination therapy of pBTZ169, bedaquiline, and pyrazinamide was more effective than the frontline TB regimen in murine models.<sup>10</sup> Moreover,

Lechartler et. al. recently demonstrated that the combination of clofazimine, a frontline anti-leprosy agent with pBTZ169 was found to be synergistic against both replicating and nonreplicating *Mtb*.<sup>11</sup> Intuitively, agents can be designed in a way that they might have multiple targets. Therefore, we envisioned chemical conjugation of 1,3-benzothiazin-4-ones, DprE1 with 7-acylamino cephalosporins 2.7inhibitors, and dimethylimidazo[1,2-a]pyridine-3-carboxylic acids. Cephalosporins and BTZs target the peptidoglycan and arabinogalactan component of the bacterial cell wall respectively, whereas the imidazo[1,2-a]pyridine-3-carboxamides have been shown to inhibit the cellular energy dependent process.

The  $\beta$ -lactam family continues to be a hallmark of medicinal chemistry, having been discovered over 80 years ago, yet still making up the majority of the antibiotic market. Currently, the cephalosporin class of  $\beta$ -lactam antibiotics is the most widely used type of  $\beta$ -lactam, with sales estimated at 11.9 billion dollars, topping the list of antibacterial agents in 2009.<sup>13</sup> As shown in Figure 2, one of the reasons the cephalosporins have endured the test of time is because a multitude of different functionalities have been successfully incorporated at the C-3' position of the cephalosporin core (1). To date, a myriad of different agents, such as quinolone antibiotics (1)<sup>14</sup> and pyridyl *N*-oxide toxins (2)<sup>15</sup> have been conjugated to the cephalosporin core. With the above precedence in mind, we focused on the syntheses and anti-TB evaluations of conjugates of pBTZs and cephalosporins.



Figure 2. Two examples of cephalosporin conjugates previously reported

The major scaffolds considered for this study are illustrated in Figure 3. Our synthetic strategy involved the synthesis of the 1,3-benzothiazin-4-one scaffold, wherein we opted to utilize the core of the recently reported analog of BTZ043, pBTZ,<sup>16</sup> as one can introduce appropriate substituents at the terminal piperazinyl nitrogen potentially without affecting the target interaction (DprE1) with the nitro aromatic functionality. The next part involved syntheses of imidazopyridine-pBTZ conjugate without (Scheme 2) and with (Scheme 3) different linkers. Lastly, the syntheses of appropriately functionalized cephalosporins were performed (Schemes 4 and 5).



Figure 3. Scaffolds of interest in this study

The primary scaffold, pBTZ (Figure 3) for synthetic and biological activity studies, was synthesized as a TFA salt by removing the Boc group of its *N*-Boc-protected precursor (Boc-pBTZ-Boc, Figure 3), which in turn was synthesized according to the published procedure.<sup>17</sup> For the syntheses of our first pBTZ-imidazopyridine conjugate, a previously published procedure was used to generate the necessary carboxylic acid.<sup>18</sup> This intermediate was then reacted with pBTZ to give conjugate **4** (Scheme 1).



Scheme 1. Synthesis of pBTZ-imidazopyridine conjugate (4) without any linker.

In order to explore the effect of a linker between pBTZ and the imidazopyridine scaffold, we chose to incorporate 4aminomethyl benzoic acid as a representative amino acid linker. As shown in Scheme 2, the Boc group of benzyl 4-(((*tert*butoxycarbonyl)amino)methyl)benzoate (5) was deprotected and the subsequent amine (6) was coupled with 3 to obtain 2,7dimethylimidazo[1,2-a]pyridine-3-carboxamide, 7. Compound 7 was then subjected to hydrogenolysis to give carboxylic acid 8 which was used without further purification for coupling with pBTZ in the presence of tetramethylfluoroformamidinium hexafluorophosphate (TFFH) and DIPEA to obtain the final conjugate 9 in 36% yield.



Scheme 2. Syntheses of pBTZ-imidazopyridine conjugate 9.

For our syntheses of pBTZ-cephalosporin conjugates, we began with the construction of two activated cephalosporins for eventual pBTZ conjugation. As shown in Scheme 3, starting

with commercially available 7-aminocephalosporanic acid (7-ACA), *tert*-butyl esterification<sup>19</sup> followed by acylation and enzymatic deprotection<sup>20</sup> gave **10**. The hydroxyl group was then converted to an activated carbonate by reaction with 1,2,2,2-tetrachloroethylchloroformate to give **11**. Cephalosporin **11** was then coupled to pBTZ to give **12** and deprotection with TFA gave conjugate **13**.



Scheme 3. Synthesis of pBTZ-Cephalosporin 13-

As with our pBTZ-imidazopyridine syntheses, we were also interested in exploring the effect of a linker on the anti-TB activities of the cephalosporin-pBTZ conjugates. As a result of the lipophilic cell wall (thick layer of mycolic acids) characteristic of *Mtb*, we tested various protected cephalosporinpBTZ conjugates to see whether these more lipophilic protected cephalosporins would exhibit anti-TB activity. As shown in Scheme 4, we started with cephalosporin 10. Reaction with thionyl chloride gave 14a in good yield and subsequent reactions of 14a and 14b (commercially available) with NaI and pBTZ gave intermediates 15a-b. Deprotection of 15b with TFA gave conjugate 16.

All compounds were then subjected to anti-TB evaluations against *Mtb* in the Microplate Alamar Blue assay (MABA).<sup>21</sup> As shown in Table 1, a number of compounds exhibited good activity against Mtb including the broad activity that conjugates 4 and 15a exhibited against the H37Rv strain of Mtb in two different mycobacterial growth media (7H12 and GAS). Although notable, the observed activities of all highlighted conjugates were still significantly lower than either the prototype imidazopyridine analogs or pBTZ 169, BTZ043 or the precursor pBTZ-Boc. The anti-TB evaluations of conjugate 9 indicated that the introduction of a linker between the imidazopyridine scaffold and pBTZ was detrimental for anti-TB activity. We additionally explored the syntheses and anti-TB evaluations of amino acid linkers such as  $\beta$ -alanine and  $\gamma$ -aminobutyric acid (see Supporting Information). Nevertheless, the anti-TB evaluations of these conjugates again indicated that the presence of a linker had a deleterious effect on the anti-TB activity.

Interestingly, however, one of the imidazopyridine intermediates (7) for the syntheses of conjugate 9 was quite active with an MIC of 0.21  $\mu$ M in 7H12 media and 4.1  $\mu$ M in GAS media. Often, differences in activity in different media occur as the result of factors such as compound solubility, different carbon sources, and media age.<sup>22</sup>



Scheme 4. Synthesis of pBTZ-cephalosporin 16.

SAR studies of the cephalosporin-pBTZ conjugates also revealed some media dependent activity against *Mtb*. Conjugate **15a** was the most active, with MIC values of 2.03 and 1.51  $\mu$ M in the 7H12 and GAS media, respectively. The difference in activity between conjugates **13** and **16**; however, was somewhat surprising. Since both conjugates possessed the free carboxylate normally associated with potentiating  $\beta$ -lactams for activity, it was anticipated that activity might have been enhanced. Instead, the protected conjugates, (e.g. **12** and **15a**) were more potent agents in general. This may be due to the greater lipophilicity of these intermediates relative to their free acid counterparts, thus allowing entry into *Mtb*. Interestingly, however, intermediate **15b** was completely devoid of activity. Thus, it seemed that the choice of protecting group might significantly activate or deactivate these compounds.

**Table 1.** MIC Determinations  $(\mu M)$  for Select Compounds Against *Mycobacterium Tuberculosis* (H37Rv)in the Microplate Alamar Blue Assav (MABA).

Cmpd.	7H12 <sup>a</sup>	GAS <sup>b</sup>	Cmpd.	7H12 <sup>a</sup>	GAS <sup>b</sup>	
4	2.10	1.43	16	86.8	48.9	
7	0.21	4.10	Rifampin	0.05	0.04	
9	>10	>10	BTZ-043	<0.004	<0.004	
11	>50	22.22	pBTZ-Boc	0.28	<0.20	
12	1.49	63.45				
13	4.63	11.96				
15a	2.03	1.51				
15b	>100	>100				
<sup>a</sup> 7H12 = 7H9 medium + casitone, palmitric acid, albumin, and catalase; <sup>b</sup> GAS = glycerol-alanine salts medium						

3.

Lastly, cephalosporin-pBTZ conjugates were also screened for antibacterial activity. As shown in Table 2, the conjugates targeted Gram-positive bacteria, exhibiting both potent zones of inhibition (see Supporting Information) and MIC values. Of outstanding interest was both cephalosporin-pBTZ conjugates **13** and **16**, demonstrating notable inhibition against *M. vaccae* and *B. subtilis*, with MICs of 0.2  $\mu$ M and <0.003  $\mu$ M, respectively.

Table 2. Minimum Inhibitory Determinations (µM) for Select Compounds.

Cmpd.	B. subtilis	S. aureus	M. luteus	M. vaccae
	ATCC 6633	\$G511	ATCC 10240	IMET 10670
$1, \mathbf{X} = \mathbf{OAc}$	<0.1	0.2	3.13	nt
BTZ043	nt	>200	>200	0.03
13	0.80-1.60	12.5	nt	0.20
15a	1.56	12.5	nt	0.8
15b	0.1-0.2	1.56	nt	nt
16	<0.003	0.4	1.56	12.5
Ciprofloxicin	0.15-0.32	nt	nt	nt

Compounds were dissolved in MeOH/DMSO

To summarize, we have synthesized a focused set of conjugates between pBTZ and both imidazopyridines and 7-phenylacetamido cephalosporins and tested them for anti-TB activity in the MABA assay. The product of direct conjugation between pBTZ and imidazopyridine (compound 4) exhibited anti-TB activity albeit not as impressive as its precursors and the introduction of linkers between the two precursor scaffolds in 4 resulted in dramatic loss of activity. Anti-TB activity was observed only for the very lipophilic 15a, whereas similarly lipophilic analog 15b was completely inactive. Potent Grampositive antibacterial activity was seen for cephalosporin-pBTZ conjugates 13 and 15-16.

#### Acknowledgments

We acknowledge the University of Notre Dame, and the NIH (NIH-2R01-AI054193-05A2) for support of this work. We acknowledge Nonka Sevova (Mass Spectrometry and Proteomics Facility, UND) for mass spectroscopic analyses and Viktor Krchňák for LC/MS and prep LC assistance. M.W.M acknowledges an ECK Global Health Fellowship (2014-2015, UND).

#### **References and notes**

- 1. Global Tuberculosis Report 2014, http://www.who.int/tb/publications/global\_report/en/
- Gandhi, N. R.; Nunn, P.; Dheda, K.; Schaaf, H. S.; Zignol, M.; Van Soolingen D.; Jensen, P.; Bayona, J. *Lancet* 2010, *375*, 1830-1843.

- Zumla, A.; Nahid, P.; Cole, S.T. Nat. Rev. Drug Dis. 2013, 12, 388-404.
- Trefzer, C.; Skovierova, H.; Buroni, S.; Bobovska, A.; Nenci, S.; Molteni, E.; Pojer, F.; Pasca, M. R.; Makarov, V.; Cole, S. T.; Riccardi, G.; Mikusova, K.; Johnsson, K. J. Am. Chem. Soc. 2012, 134, 912-915.
- a) Minarini, P. R. R.; de Souza, A. O.; Soares, E. G.; Barata, L. E. S.; Silva, C. L.; Bentley, M. V. Maria Vitoria, L. B. *Drug. Dev. Ind. Pharm.* 2012, 38, 259-263. b) http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm c) Zumla, A.; Raviglione, M.; Hafner, R.; von Reyn, C. F. N. Engl. J. *Med*. 2013, 368, 745-755.
- Zumla, A.; Raviglione, M.; Hafner, R.; von Reyn, C. F. N. Engl. J. Med. 2013, 368, 745-755.
- Singh, R.; Manjunatha, U.; Boshoff, H. I. M.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E. III, Science 2008, 322, 1392-1395.
- Makarov, V.; Manina, G.; Mikusova, K.; Mollmann, U.; Ryabova, O.; Saint-Joanis, B.; Dhar, N.; Pasca, M. R.; Buroni, S.; Lucarelli, A. P.; Milano, A.; De Rossi, E.; Belanova, M.; Bobovska, A.; Dianiskova, P.; Kordulakova, J.; Sala, C.; Fullam, E.; Schneider, P.; McKinney, J. D.; Brodin, P.; Christophe, T.; Waddell, S.; Butcher, P.; Albrethsen, J.; Rosenkrands, I.; Brosch, R.; Nandi, V.; Bharath, S.; Gaonkar, S.; Shandil, R. K.; Balasubramanian, V.; Balganesh, T.; Tyagi, S.; Grosset, J.; Riccardi, G.; Cole, S. T. Science 2009, 324, 801-804.

Cheng, Y.; Moraski, G. C.; Cramer, J.; Miller, M. J.; Schorey J. S. *PLoS One.* **2014**, *9*, e87483.

Makarov, V.; Lechartier, B.; Zhang, M.; Neres, J.; van der Sar, A. M.; Raadsen, S. A.; Hartkoorn, R. C.; Ryabova, O. B.; Vocat, A.; Decosterd, L. A.; Widmer, N.; Buclin, T.; Bitter, W.; Andries, K.; Pojer, F.; Dyson, P. J.; Cole, S. T. *EMBO Mol. Med.* **2014**, *6*, 372-383.

- 11. Lechartier, B.; Hartkoorn, R. C.; Cole, S. T. Antimicrob. Agents Chemother. 2012, 56, 5790-5793.
- Moraski, G. C.; Markley, L. D.; Hipskind, P. A.; Boshoff, H; Cho, S.; Franzblau, S. G.; Miller, M. J. ACS Med. Chem. Lett. 2011, 2, 466-470.
- 13. Hamad, B. Nat. Rev. Drug Dis. 2010, 9, 675-676.
- a) Albrecht, H. A.; Beskid, G.; Christenson, J. G.; Deitcher, K. H.; Georgopapadakou, N. H.; Keith, D. D.; Konzelmann, F. M.; Pruess, D. L.; Wei, C. C. J. Med. Chem. 1994, 37, 400-407. b) Albrecht, H. A.; Christenson, J. G. Adv. Med. Chem. 1992, 1, 207-234.
- O'Callaghan, C. H.; Sykes, R. B.; Staniworth, S. E. Antimicrob. Agents Chemother. 1976, 10, 245-248.
- Gao, C.; Ye, T. H.; Wang, N. Y.; Zeng, X. X.; Zhang, L. D.; Xiong, Y.; You, X. Y.; Xia, Y.; Xu, Y.; Peng, C. T.; Zuo, W. Q.; Wei, Y.; Yu, L.T. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 4919-4922.
- Peng, C. T.; Gao, C.; Wang, N. Y.; You, X. Y.; Zhang, L. D.; Zhu, Y. X.; Xv, Y.; Zuo, W. Q.; Ran, K.; Deng, H. X.; Lei, Q.; Xiao, K. J.; Yu, L. T.; *Bioorg. Med. Chem. Lett.* **2015**, *25*, 1373-1376.
- Moraski, G. C.; Markley, L. D.; Cramer, J.; Hipskind, P. A.; Boshoff, H.; Bailey, M. A.; Alling, T.; Ollinger, J.; Parish, T.; Miller, M. J. ACS Med. Chem. Lett. 2013, 4, 675-679.
- Glinka, T.; Huie, K.; Cho, A.; Ludwikow, M.; Blais, J.; Griffith, D.; Hecker, S.; Dudley, M. *Bioorg. Med. Chem.* 2003, *11*, 591-600.

KEY: B. subtilis = Bacillus subtilis, S. aureus. = Staphylococcus aureus, M. luteus = Micrococcus luteus, M. vaccae = Mycobacterium vaccae. nt = not tested

- 20. Patterson, L. D.; Miller, M. J. J. Org. Chem. 2010, 75, 1289-1292.
- 21. a) Collins, L.; Franzblau, S. G. Antimicrob. Agents *Chemother.* **1997**, *41*, 1004-1009. b) DeVoss, J. J.; Rutter, K.; Schroeder, B.; Su, H.; Zhu, Y.; Barry, C. E. *3<sup>rd</sup> Proc. Natl. Acad.* Sci. USA. 2000, 97, 1252-1257. c) Cho, S. H.; Warit, S.; Wan, B.; Hwang, C. H.; Pauli, G. F.; Franzblau, S. G. Antimicrob. Agents Chemother. 2007, 51, 1380-1385.
- Acceleration 22.

#### **Supplementary Material**

Synthetic procedures, compound characterization data, and MABA assay procedures are available online. This material is available free of charge via the Internet.